Abstract
Data from many experiments has shown that serotonin2C (5-HT2C) receptor plays a role in the control of orofacial activity in rodents. Purposeless oral movements can be elicited either by agonists or inverse agonists implying a tight control exerted by the receptor upon oral activity. The effects of agonists has been related to an action of these drugs in the subthalamic nucleus and the striatum, the two input structures for cortical efferents to the basal ganglia, a group of subcortical structures involved in the control of motor behaviors. The oral effects of agonists are dramatically enhanced in case of chronic blockade of central dopaminergic transmission induced by neuroleptics or massive destruction of dopamine neurons. The mechanisms involved in the hypersensitized oral responses to 5-HT2C agonists are not clear and deserve additional studies. Indeed, while the oral behavior triggered by 5-HT2C drugs would barely correspond to the dyskinesia observed in humans, the clinical data have consistently postulated that 5-HT2C receptors could be involved in these aberrant motor manifestations.
Keywords: Serotonin2c receptor, oral activity, neuroleptic, 6-hydroxydopamine lesion, hypersensitized oral responses
Current Neuropharmacology
Title:Serotonin2C Receptors and the Motor Control of Oral Activity
Volume: 11 Issue: 2
Author(s): Melanie Lagiere, Sylvia Navailles, Marion Bosc, Martin Guthrie and Philippe De Deurwaerdere
Affiliation:
Keywords: Serotonin2c receptor, oral activity, neuroleptic, 6-hydroxydopamine lesion, hypersensitized oral responses
Abstract: Data from many experiments has shown that serotonin2C (5-HT2C) receptor plays a role in the control of orofacial activity in rodents. Purposeless oral movements can be elicited either by agonists or inverse agonists implying a tight control exerted by the receptor upon oral activity. The effects of agonists has been related to an action of these drugs in the subthalamic nucleus and the striatum, the two input structures for cortical efferents to the basal ganglia, a group of subcortical structures involved in the control of motor behaviors. The oral effects of agonists are dramatically enhanced in case of chronic blockade of central dopaminergic transmission induced by neuroleptics or massive destruction of dopamine neurons. The mechanisms involved in the hypersensitized oral responses to 5-HT2C agonists are not clear and deserve additional studies. Indeed, while the oral behavior triggered by 5-HT2C drugs would barely correspond to the dyskinesia observed in humans, the clinical data have consistently postulated that 5-HT2C receptors could be involved in these aberrant motor manifestations.
Export Options
About this article
Cite this article as:
Lagiere Melanie, Navailles Sylvia, Bosc Marion, Guthrie Martin and Deurwaerdere De Philippe, Serotonin2C Receptors and the Motor Control of Oral Activity, Current Neuropharmacology 2013; 11 (2) . https://dx.doi.org/10.2174/1570159X11311020003
DOI https://dx.doi.org/10.2174/1570159X11311020003 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Supercritical Fluid Chromatographic Method for Montelukast: Application in Content Uniformity and Degradation Study
Current Analytical Chemistry Molecular Targets of Tannic Acid in Alzheimer's Disease
Current Alzheimer Research Preface
Current Medicinal Chemistry Amelioration of Myocardial Ischemic Reperfusion Injury with Calendula Officinalis
Current Pharmaceutical Biotechnology Antinuclear Antibodies and Lupus-like Manifestations in Rheumatoid Arthritis and Ankylosing Spondylitis Patients at 4 Months' Follow-up After Treatment with Infliximab and Etanercept
Current Rheumatology Reviews Cyclotides, a Novel Ultrastable Polypeptide Scaffold for Drug Discovery
Current Pharmaceutical Design Research Strategies for Pain in Lumbar Radiculopathy Focusing on Acid-Sensing Ion Channels and Their Toxins
Current Topics in Medicinal Chemistry Polyamines in Gut Inflammation and Allergy
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Protective Effect of Aspirin Against Oligomeric Aβ42 Induced Mitochondrial Alterations and Neurotoxicity in Differentiated EC P19 Neuronal Cells
Current Alzheimer Research Astrocytes: Targets for Neuroprotection in Stroke
Central Nervous System Agents in Medicinal Chemistry Molecular Pathways of Endothelial Cell Activation for (Targeted) Pharmacological Intervention of Chronic Inflammatory Diseases
Current Vascular Pharmacology Global Expression Studies of Schizophrenic Brain: A Meta-Analysis Study Linking Neurological Immune System with Psychological Disorders
CNS & Neurological Disorders - Drug Targets Peptide-Based Nanostructures for Cancer Diagnosis and Therapy
Current Medicinal Chemistry Use of Systemic Proteasome Inhibition as an Immune-Modulating Agent in Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets subject Index To Volume 1
Current Drug Targets - Inflammation & Allergy Glycogen Synthase Kinase-3 in Neurodegeneration and Neuroprotection:Lessons from Lithium
Current Alzheimer Research Protein-Protein Interactions in Drug Discovery
Drug Design Reviews - Online (Discontinued)